Why Do We Have to Use Chemotherapy?

  • Noelia Tarazona
  • Valentina Gambardella
  • Marisol Huerta
  • Andrés Cervantes
Chapter

Abstract

The use of chemotherapy (CT) in localized rectal cancer (LARC) has two aims: first, to improve the local effect of radiotherapy by giving concomitant chemoradiation and second, to decrease systemic relapses by early treatment for occult micrometastatic disease or to shrink bulky local tumours. Neoadjuvant treatment is reserved for locally advanced disease, as defined by pelvic magnetic resonance imaging, a very useful and accurate tool to identify high-risk features for local or systemic relapse [1]. We are going to address why we have to use CT in LARC.

References

  1. 1.
    Smith NJ, Shihab O, Arnaout A et al (2008) MRI for detection of extramural vascular in rectal cancer. AJR Am J Roentgenol 191:1517–1522CrossRefPubMedGoogle Scholar
  2. 2.
    Rödel C, Liersch T, Hermann R et al (2007) Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 25:668–674Google Scholar
  3. 3.
    Sebarg-Montefiore D, Rutten H, Rullier E et al (2009) Three-year survival results of CORE (capecitabine, oxaliplatin, radiotherapy, and excision) study after postoperative chemotherapy in patients with locally advanced rectal adenocarcinoma. ASCO GI Meeting Abstracts 447Google Scholar
  4. 4.
    Glynne-Jones R, Grainger J, Harrison J et al (2006) Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious? Br J Cancer 94:363–371CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Chau I, Brown G, Cunningham D et al (2005) Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 24:668–674CrossRefGoogle Scholar
  6. 6.
    Dewdney A, Cunningham D, Tabernero J et al (2012) Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 30:1620–1627CrossRefPubMedGoogle Scholar
  7. 7.
    Fernández-Martos C, Pericay C, Aparicio J et al (2010) Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 28:859–865CrossRefPubMedGoogle Scholar
  8. 8.
    Nilsson PJ, van Etten B, Hospers GA et al (2013) Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial. BMC Cancer 13:279CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Bujko K, Wyrwicz L, Rutkowski A, et al (2016) Long-course oxaliplatin based preoperative chemoradiation vs. 5 x 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomised phase III study. Ann Oncol 27. doi: 10.1093/annonc/mdw062
  10. 10.
    García-Aguilar J, Chow OS, Smith DD et al (2015) Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase II trial. Lancet Oncol 16:957–966CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Bosset JF, Collete L, Calais G et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123CrossRefPubMedGoogle Scholar
  12. 12.
    Sauer R, Liersch T, Merkel S et al (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow up of 11 years. J Clin Oncol 30:1926–1933CrossRefPubMedGoogle Scholar
  13. 13.
    Gerard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625CrossRefPubMedGoogle Scholar
  14. 14.
    Bosset JF, Calais G, Mineur L et al (2005) Enhanced tumoricidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preeliminary results-EORTC 22921. J Clin Oncol 23:5620–5627CrossRefPubMedGoogle Scholar
  15. 15.
    Allegra CJ, Yothers G, O’Connell MJ, et al (2015) Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst 107. doi:  10.1093/jnci/djv248
  16. 16.
    Aschele C, Cionini L, Lonardi S et al (2011) Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29:2773–2780CrossRefPubMedGoogle Scholar
  17. 17.
    Gérard JP, Azria D, Gourgou-Bourgade S et al (2012) Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 30:4558–4565CrossRefPubMedGoogle Scholar
  18. 18.
    Resende HM, Jacob LFP, Quinellato LV, Matos D, da Silva EMK (2015) Combination chemotherapy versus single-agent chemotherapy during preoperative chemoradiation for resectable rectal cancer. Cochrane Database Syst Rev 10:CD008531Google Scholar
  19. 19.
    Gunderson LL, Sargent DJ, Tepper JE et al (2004) Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 22:1785–1796CrossRefPubMedGoogle Scholar
  20. 20.
    Sakamoto J, Hamada C, Yoshida S et al (2007) An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. Br J Cancer 96:1170–1177CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Quasar Collaborative Group, Gary R, Barnwell J et al (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370:2020–2029CrossRefGoogle Scholar
  22. 22.
    Petersen HS, Harling H, Kirkeby LT et al (2012) Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 3:CD004078Google Scholar
  23. 23.
    Breugom AJ, Swets M, Bosset JF et al (2015) Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16:200–207CrossRefPubMedGoogle Scholar
  24. 24.
    Hong YS, Nam BH, Kim KP et al (2014) Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 15:1245–1253CrossRefPubMedGoogle Scholar
  25. 25.
    Rödel C, Graeven U, Fietkau R et al (2015) Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 16:979–989CrossRefPubMedGoogle Scholar
  26. 26.
    Schmoll HJ, Haustermans K, Price TJ et al (2014) Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: first results of the PETACC-6 randomized phase III trial. Proc Am Soc Clin Oncol 32 (abstract 3501)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2018

Authors and Affiliations

  • Noelia Tarazona
    • 1
    • 2
  • Valentina Gambardella
    • 1
    • 3
  • Marisol Huerta
    • 1
  • Andrés Cervantes
    • 1
  1. 1.Department of Medical OncologyBiomedical Research Institute INCLIVA, University of ValenciaValenciaSpain
  2. 2.Rio Hortega Contract CM15/00246ValenciaSpain
  3. 3.ESMO Translational Research FellowValenciaSpain

Personalised recommendations